Sigyn Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q2 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Sigyn Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q2 2021 to Q3 2024.
  • Sigyn Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $127K, a 30% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $127K -$54.2K -30% Sep 30, 2024 10-Q 2024-11-19
Q2 2024 $141K -$52.7K -27.3% Jun 30, 2024 10-Q 2024-08-19
Q1 2024 $154K -$51.3K -25% Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $168K -$50K -23% Dec 31, 2023 10-Q 2024-11-19
Q3 2023 $181K -$48.7K -21.2% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $193K -$47.4K -19.7% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $206K -$46.2K -18.3% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $218K -$45.1K -17.1% Dec 31, 2022 10-K 2024-02-20
Q3 2022 $229K -$46.9K -17% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $241K -$46.4K -16.1% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $252K Mar 31, 2022 10-Q 2022-05-13
Q4 2021 $263K Dec 31, 2021 10-K 2023-03-31
Q3 2021 $276K Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $287K Jun 30, 2021 10-Q 2021-08-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.